MicroMass recruits three strategy vets

Share this article:
MicroMass Communications has added three new VP, senior strategists to better address the marketing shift from mass-market communications to a more patient-focused approach.

Account planning veteran Mark Klapper joins the Cary, NC-based relationship marketing agency from Unit 7, where he led planners, analysts and psychologists as EVP, director of planning and consulting services.

Kim Levy, a 17-year pharma marketing veteran of both the corporate and agency sides, joins MicroMass to develop strategy on the agency's oncology accounts. Prior to joining MicroMass, Levy was at Adair-Greene Healthcare Communications.

Rick Mazzetti joins MicroMass with over 20 years of pharma industry experience including marketing, sales management and alliance management positions at GlaxoSmithKline, Quintiles Transnational, and LipoScience. His previous brand management experience lies in the areas of central nervous system, cardiology, women's health, men's health, dermatology, and antibiotics.
President Jay Bigelow said in a statement that these new hires come as the agency addresses the ongoing industry shift away from investing in direct-to-consumer advertising.

“With increased pressure to cut back on direct-to-consumer advertising, we are finding that more and more brands are looking for alternate strategies to communicate with patients and professionals, such as relationship marketing and disease awareness campaigns,” Bigelow said. “Enhanced by these new hires, our strategic services group… [will] help clients navigate through this change.”

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...